Metabolic & Fat-Loss Peptides

Target: NNMT (nicotinamide N-methyltransferase) inhibitor

5-Amino-1MQ is a small molecule that inhibits NNMT (nicotinamide N-methyltransferase), an enzyme linked to fat accumulation and metabolic dysfunction. By blocking NNMT, it may increase NAD+ levels, boost cellular energy, promote fat loss, and support metabolic health. Studied for obesity, type 2 diabetes, and longevity applications.

Target: C-terminal hGH fragment (fat metabolism)

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191) studied for fat metabolism and weight loss. It mimics GH's lipolytic effects without affecting blood sugar or growth. Previously in clinical trials for obesity; now popular in research settings.

Target: Amylin & calcitonin receptors

Cagrilintide is Novo Nordisk's long-acting amylin analog designed for weight management. Phase 2 trials showed 11.8% body weight loss as monotherapy and up to 17.1% when combined with semaglutide (CagriSema). Works by enhancing satiety and slowing gastric emptying through amylin receptor activation.

Target: ERRα/β/γ (estrogen-related receptor pan-agonist)

A small-molecule ERR receptor agonist that acts like exercise inside your cells — driving mitochondrial biogenesis, fat oxidation, and endurance gains without any actual training.

Target: Serotonin–norepinephrine–dopamine reuptake inhibitor

Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI) originally developed for Parkinson's and Alzheimer's disease. Phase 2 trials showed remarkable weight loss of up to 12.8% over 6 months — more than double most approved obesity drugs. Works by reducing appetite and increasing satiety through triple monoamine reuptake inhibition.